CTOs on the Move


 
Vical Incorporated researches and develops biopharmaceutical products based on its deoxyribonucleic acid (DNA) delivery technologies for the prevention and treatment of serious or life-threatening diseases. The Company has three active independent
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million
  • www.vical.com
  • 10390 Pacific Center Ct
    San Diego, CA USA 92121
  • Phone: 858.646.1100

Executives

Name Title Contact Details

Similar Companies

Canadian Phamacy Online

Canadian Phamacy Online is a Winnipeg, MB-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Visus Therapeutics

Visus Therapeutics is a clinical-stage company in pursuit of developing the world`s first presbyopia-correcting eye drop with the potential to last at least eight hours. With offices in Seattle, Washington, and Orange County, California, our lead clinical candidate is VTI-001 (BRIMOCHOL™), a once-daily eye drop designed to correct the loss of near vision associated with presbyopia. In parallel, Visus Therapeutics is focused on advancing its pipeline of early-stage ophthalmic product candidates.

New Health Sciences

New Health Sciences is developing Hemanext, a technology designed to improve the safety and efficacy of transfusion therapy through novel storage methods.

Gilead

Gilead Sciences is a biopharmaceutical company that discovers, develops and commercializes innovative therapeutics in areas of unmet medical need. The company`s mission is to advance the care of patients suffering from life-threatening diseases. Gilead has operations in more than 30 countries worldwide, with headquarters in Foster City, California.

Merus

Merus is developing best-in-class therapeutics to treat and potentially cure cancer patients. Our most advanced development programs use the Biclonics® format. Biclonics® are capable of simultaneously attacking tumors in multiple ways. For example by activating the immune system to kill tumor cells and directly inhibiting tumor cell growth and survival pathways.